Comparative statistical analysis of osteoporosis treatment based on Hungarian claims data and interpretation of the results in respect to cost-effectiveness

被引:7
作者
Lakatos, P. [1 ]
Toth, E. [2 ]
Szekeres, L. [3 ]
Poor, G. [3 ]
Hejj, G. [3 ]
Marton, I. [4 ]
Takacs, I. [1 ]
机构
[1] Semmelweis Univ, Dept Med 1, H-1083 Budapest, Hungary
[2] Healthware Consulting Ltd, Budapest, Hungary
[3] Natl Inst Rheumatism & Physiotherapy, Budapest, Hungary
[4] Hungarian Soc Osteoporosis & Osteoarthrol, Budapest, Hungary
关键词
Cost-effectiveness; Fractures; Hospitalization; Osteoporosis; Treatment; HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; VERTEBRAL FRACTURES; NONVERTEBRAL FRACTURES; STRONTIUM RANELATE; PROPENSITY SCORE; RANDOMIZED-TRIAL; WOMEN; RISK; EPIDEMIOLOGY;
D O I
10.1007/s00198-014-2733-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The efficacy of interventions used in real life for the treatment of osteoporosis has not been evaluated on a national basis. We analysed the database of the single Hungarian health care provider between 2004 and 2010. A marked reduction in fracture incidence and hospitalization was seen, which also proved to be cost-effective. Osteoporosis and its consequences place a significant burden on the health care systems of developed countries. Present therapeutic modalities are effective in reducing the risk of fractures caused by osteoporosis. However, we do not know whether the interventions introduced in the past 15 years have significantly reduced the number of osteoporotic fractures in real life, and if yes, how cost-effectively. The database of the National Health Insurance Fund Administration in Hungary was analysed for the period between 2004 and 2010. Two specific patient groups were identified within the population. Patients, who were under osteoporosis treatment in more than 80 % of the potential treatment days in three consecutive years (patients with high compliance), were compared with patients where this ratio was under 20 % (patients with low compliance). Several statistical comparative models were implemented in order to capture a complete picture on the differences. Because of natural data heterogeneity of administration databases, propensity matching was applied as well. Comparing treated vs. control subjects, patients with high compliance showed a significant decrease in fracture risk and hospitalization, which was more robust after propensity adjustment. On the basis of the observed statistically significant differences, cost-effectiveness analysis was implemented. Utility loss due the observed fractures was compared with the total cost differences of the two arms based on modelling. Our calculations proved the cost-effectiveness of the long-term high compliance in real world settings. Our findings infer that the standardized and uniform health care of osteoporotic patients in a country may reduce general fracture incidence and hospitalization in a cost-effective way.
引用
收藏
页码:2077 / 2087
页数:11
相关论文
共 50 条
  • [41] Cost and effectiveness analyses of the anti-osteoporosis medication in patients with hip fracture in Taiwan: A population-based national claims database analysis
    Wang, Chen-Yu
    Wu, Chih-Hsing
    Chen, Ho-Min
    Lin, Jou-Wei
    Hsu, Chih-Cheng
    Chang, Yin-Fan
    Tai, Ta-Wei
    Fu, Shau-Huai
    Hwang, Jawl-Shan
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2023, 122 : S92 - S100
  • [42] HMG versus rFSH for ovulation induction in developing countries: a cost-effectiveness analysis based on the results of a recent meta-analysis
    Al-Inany, H
    Abou-Setta, AM
    Aboulghar, MA
    Mansour, RT
    Serour, GI
    [J]. REPRODUCTIVE BIOMEDICINE ONLINE, 2006, 12 (02) : 163 - 169
  • [43] Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation-results for Canada, Italy, Sweden and Switzerland
    Nilsson, Jonas
    Akerborg, Orjan
    Bego-Le Bagousse, Gaelle
    Rosenquist, Marten
    Lindgren, Peter
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2013, 14 (03) : 481 - 493
  • [44] Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis
    Centonze, Diego
    Iannazzo, Sergio
    Santoni, Laura
    Saleri, Cecilia
    Puma, Elisa
    Giuliani, Luigi
    Canonico, Pier Luigi
    [J]. FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2018, 19 (01) : 47 - 52
  • [45] Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach
    Williams, Jack
    Roberts, Ian
    Shakur-Still, Haleema
    Lecky, Fiona E.
    Chaudhri, Rizwana
    Miners, Alec
    [J]. BMJ GLOBAL HEALTH, 2020, 5 (09):
  • [46] Evidence-based scientific data documenting the treatment and cost-effectiveness of comprehensive pain programs for chronic nonmalignant pain
    Gatchel, Robert J.
    Okifuji, Akiko
    [J]. JOURNAL OF PAIN, 2006, 7 (11) : 779 - 793
  • [47] Cost-Effectiveness of Proton Versus Photon Therapy in Pediatric Medulloblastoma Treatment: A Patient Volume-Based Analysis
    Alves Fernandes, Ricardo Ribeiro
    de Mello Vianna, Cid Manso
    Guerra, Renata Leborato
    Cancela, Marianna de Camargo
    de Almeida, Liz Maria
    da Conceicao Pereira, Adail Jose
    Pais Viegas, Celia Maria
    Ferman, Sima Esther
    de Correa, Flavia
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2019, 20 : 122 - 128
  • [48] Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial
    Huang, Jiaxing
    Liao, Weiting
    Zhou, Jing
    Zhang, Pengfei
    Wen, Feng
    Wang, Xinyuan
    Zhang, Mengxi
    Zhou, Kexun
    Wu, Qiuji
    Li, Qiu
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 4065 - 4072
  • [49] We shouldn't count chickens before they hatch: results-based financing and the challenges of cost-effectiveness analysis
    Paul, Elisabeth
    Brown, Garrett W.
    Ensor, Tim
    Ooms, Gorik
    van de Pas, Remco
    Ridde, Valery
    [J]. CRITICAL PUBLIC HEALTH, 2021, 31 (03) : 370 - 375
  • [50] The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly
    J Lundkvist
    M Ekman
    B Kartman
    J Carlsson
    L Jönsson
    H Lithell
    [J]. Journal of Human Hypertension, 2005, 19 : 569 - 576